IBA Swings to EUR9.3 Million Profit as Proton Therapy Turns

Ion Beam Applications SA reported a positive net result of EUR9.3 million for the first half of 2026 and reiterated full-year adjusted EBIT guidance of at least EUR32 million, citing a return to sustainable profitability in its Proton Therapy division.

Ion Beam Applications SA (OTC: IOBCF) told investors on its first-half 2026 earnings call that the company finished the period with a positive net result of EUR9.3 million, and that its Proton Therapy business — the part of the group that builds and services the accelerators used to treat cancer with charged particles rather than conventional X-rays — has returned to what management described as sustainable profitability.

The company also left its full-year 2026 guidance in place: adjusted EBIT of at least EUR32 million. That is the number the equity story now rests on. Adjusted EBIT is earnings before interest and tax, stripped of items management considers one-off or non-operational; it is the measure IBA has used to frame the recovery, and reiterating a floor rather than trimming it is the more meaningful signal in a business that has historically struggled to convert a large order book into reliable operating profit.

Why Proton Therapy profitability is the whole argument

Proton therapy equipment is a long-cycle, project-based business. A single centre takes years from contract signature to clinical handover, revenue is recognised across that build, and a mis-priced contract or a slipped installation schedule can absorb the margin of two profitable ones. That is why the division has been the swing factor in IBA's results for years, and why a stated return to sustainable profitability carries more weight than a single half-year of black ink.

The distinction management is drawing matters for how investors should read the EUR9.3 million. A net result that came from a one-time disposal, a contract settlement or a currency swing tells you little about 2027. A net result underpinned by a division that is now covering its own costs at the operating line, with a growing installed base generating service revenue, is a different proposition entirely. Service and maintenance income on installed machines is the recurring, higher-visibility layer of a business whose equipment sales are inherently lumpy — and it grows mechanically as more centres come online.

Reading the guidance floor

Guidance phrased as "at least EUR32 million" is a floor, not a midpoint. Reiterating it halfway through the year implies management believes the second half carries no unpriced execution risk large enough to breach it — a reasonable posture only if the projects scheduled for completion in the remainder of 2026 are already well advanced and their margins largely locked.

What would test that? Three things, in roughly this order of likelihood: installation delays at customer sites, which push revenue recognition into the following year; cost inflation on components and field labour that cannot be passed through on contracts signed at earlier prices; and the timing of new order conversion, which affects the following year's revenue rather than this one's but shapes how the market prices the guidance anyway. None of these are IBA-specific problems. They are the standard hazards of selling capital equipment that has to be assembled inside a hospital.

The details of the half were laid out on the company's earnings call, covered by GuruFocus.

Where the shares sit

IOBCF, the over-the-counter line through which US investors access the stock, last traded at 18.51 as of the close on Wednesday, 3 September 2026, down 0.40% on the session from a previous close of 18.58. The day's range ran from 18.51 to 19.50 — the last print was at the low end of it, which is a fair reflection of an illiquid secondary listing where a handful of trades can set the day's tone rather than any considered verdict on the results.

IOBCF, the over-the-counter line through which US investors access the stock, last traded at 18.

That softness came against a firm tape elsewhere. The S&P 500 tracker (SPY) closed at $773.17, up 1.05%; the Nasdaq 100 fund (QQQ) finished at $717.67, up 1.19%; and the Dow 30 vehicle (DIA) ended at $536.93, also up 1.19%. A small-cap European medical technology name drifting slightly lower on a broadly green day says more about the mechanics of OTC trading than about the earnings themselves.

What to watch through the second half

Investors should treat the EUR32 million figure as the scoreboard and everything else as inputs to it. The specific things worth tracking:

Order intake and backlog conversion. Backlog is only as good as the schedule attached to it. Watch how much of the book is contracted for delivery inside the next twelve months versus sitting further out.
Service revenue as a share of the total. The higher this runs, the less the group's profitability depends on landing new equipment contracts in any given period.
Gross margin on equipment. This is where mis-priced legacy contracts show up. Improvement here would corroborate the "sustainable" framing.
Cash generation. Project businesses can report profit while consuming cash on working capital. Free cash flow is the harder test.
Any change in guidance language. A shift from "at least" to a range, in either direction, would be the clearest tell on how the second half is running.

The competitive backdrop

Proton therapy sits in an uncomfortable spot in oncology capital budgets. The clinical case — depositing radiation dose precisely at the tumour and sparing surrounding tissue — is strongest in paediatric cancers and tumours near critical structures, where the long-term toxicity argument is compelling. The commercial case is harder, because the machines are expensive relative to conventional linear accelerators and reimbursement varies widely by health system.

That tension has shaped the sector's development: fewer, larger centres in some markets, single-room systems designed to lower the entry cost in others. For a manufacturer, the practical consequence is a customer base of hospital systems and national health authorities making multi-year capital decisions, often with public funding attached. Orders arrive in clusters and stall in clusters, which is exactly why a company like IBA needs a service annuity underneath the equipment line to smooth results.

If the first half genuinely marks the point where that structure starts working — profitable equipment delivery on top of a growing service base — then the EUR9.3 million is the beginning of a trend rather than a good six months. The full-year print against the EUR32 million floor will be the first real check on that.

Key facts

H1 2026 net result: Positive EUR9.3 million
FY 2026 guidance: Adjusted EBIT of at least EUR32 million (reiterated)
Share price: IOBCF 18.51, -0.40%, at the close on 3 Sep 2026
Day range: 18.51–19.50; previous close 18.58

Frequently asked questions

What did Ion Beam Applications report for the first half of 2026?

IBA reported a positive net result of EUR9.3 million for the first half of 2026. Management said on the earnings call that the Proton Therapy division had returned to sustainable profitability, which has been the company's key swing factor. IBA also reiterated its full-year 2026 guidance for adjusted EBIT of at least EUR32 million.

What is adjusted EBIT and why does IBA use it?

Adjusted EBIT is earnings before interest and taxes, excluding items management treats as one-off or non-operational. Companies in long-cycle project businesses often use it to show underlying operating performance without distortion from disposals, restructuring charges or other exceptional items. For IBA it is the metric the full-year guidance floor of at least EUR32 million is set against.

Why is proton therapy a difficult business to run profitably?

Proton therapy systems are large capital installations that take years from contract signature to clinical handover, with revenue recognised across the build. A single mis-priced contract or a delayed installation can absorb the margin from other projects. Orders also arrive in clusters tied to hospital and government capital cycles, making results lumpy from period to period.

Where did IOBCF shares last trade?

IOBCF last traded at 18.51 as of the close on Wednesday, 3 September 2026, down 0.40% from a previous close of 18.58. The session range was 18.51 to 19.50, with the final print at the bottom of that band. IOBCF is an over-the-counter line, so volumes are typically thin.

How did the broader market perform on the same day?

US benchmarks closed higher on 3 September 2026. The S&P 500 tracker SPY finished at $773.17, up 1.05% on the day. The Nasdaq 100 fund QQQ ended at $717.67, up 1.19%, and the Dow 30 vehicle DIA closed at $536.93, also up 1.19%. IOBCF eased slightly against that firmer backdrop.

What should investors watch for the rest of 2026?

The main checks are order intake and how quickly backlog converts into deliverable revenue, the share of total revenue coming from service and maintenance on installed machines, equipment gross margins, and cash generation. Any change in the wording of the adjusted EBIT guidance from "at least EUR32 million" would be the clearest signal on second-half trading.

Sources

Ion Beam Applications SA (IOBCF) (H1 2026) Earnings Call Highlights: Proton Therapy Drives ... — GuruFocus

Photo: RDNE Stock project · Pexels Licence — source